12 results on '"Gustafsson, Karin L"'
Search Results
2. Estradiol and RSPO3 regulate vertebral trabecular bone mass independent of each other
- Author
-
Nilsson, Karin H., primary, Wu, Jianyao, additional, Gustafsson, Karin L., additional, El Shahawy, Maha, additional, Koskela, Antti, additional, Tuukkanen, Juha, additional, Tuckermann, Jan, additional, Henning, Petra, additional, Lerner, Ulf H., additional, Ohlsson, Claes, additional, and Movérare-Skrtic, Sofia, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Arginine site 264 in murine estrogen receptor-α is dispensable for the regulation of the skeleton
- Author
-
Gustafsson, Karin L., primary, Farman, Helen H., additional, Nilsson, Karin H., additional, Henning, Petra, additional, Movérare-Skrtic, Sofia, additional, Lionikaite, Vikte, additional, Lawenius, Lina, additional, Engdahl, Cecilia, additional, Ohlsson, Claes, additional, and Lagerquist, Marie K., additional
- Published
- 2021
- Full Text
- View/download PDF
4. The effects of estradiol are modulated in a tissue-specific manner in mice with inducible inactivation of ERα after sexual maturation
- Author
-
Ohlsson, Claes, primary, Farman, Helen H., additional, Gustafsson, Karin L., additional, Wu, Jianyao, additional, Henning, Petra, additional, Windahl, Sara H., additional, Sjögren, Klara, additional, Gustafsson, Jan-Åke, additional, Movérare-Skrtic, Sofia, additional, and Lagerquist, Marie K., additional
- Published
- 2020
- Full Text
- View/download PDF
5. Pasteurized Akkermansia muciniphila protects from fat mass gain but not from bone loss
- Author
-
Lawenius, Lina, primary, Scheffler, Julia M., additional, Gustafsson, Karin L., additional, Henning, Petra, additional, Nilsson, Karin H., additional, Colldén, Hannah, additional, Islander, Ulrika, additional, Plovier, Hubert, additional, Cani, Patrice D., additional, de Vos, Willem M., additional, Ohlsson, Claes, additional, and Sjögren, Klara, additional
- Published
- 2020
- Full Text
- View/download PDF
6. Arginine site 264 in murine estrogen receptor-a is dispensable for the regulation of the skeleton.
- Author
-
Gustafsson, Karin L., Farman, Helen H., Nilsson, Karin H., Henning, Petra, Moverare-Skrtic, Sofia, Lionikaite, Vikte, Lawenius, Lina, Engdahl, Cecilia, Ohlsson, Claes, and Lagerquist, Marie K.
- Abstract
Mutation of arginine 264 in ERα has been shown to abrogate rapid membrane ERα-mediated endothelial effects. Our novel finding that mutation of R264 is dispensable for ERα-mediated skeletal effects supports the concept that R264 determines tissue specificity of ERα. Estrogen protects against bone loss but is not a suitable treatment due to adverse effects in other tissues. Therefore, increased knowledge regarding estrogen signaling in estrogen-responsive tissues is warranted to aid the development of bone-specific estrogen treatments. Estrogen receptor-α (ERα), the main mediator of estrogenic effects in bone, is widely subjected to posttranslational modifications (PTMs). In vitro studies have shown that methylation at site R260 in the human ERα affects receptor localization and intracellular signaling. The corresponding amino acid R264 in murine ERα has been shown to have a functional role in endothelium in vivo, although the methylation of R264 in the murine gene is yet to be empirically demonstrated. The aim of this study was to investigate whether R264 in ERα is involved in the regulation of the skeleton in vivo. Dual-energy X-ray absorptiometry (DEXA) analysis at 3, 6, 9, and 12 mo of age showed no differences in total body areal bone mineral density (BMD) between R264A and wild type (WT) in either female or male mice. Furthermore, analyses using computed tomography (CT) demonstrated that trabecular bone mass in tibia and vertebra and cortical thickness in tibia were similar between R264A and WT mice. In addition, R264A females displayed a normal estrogen treatment response in trabecular bone mass as well as in cortical thickness. Furthermore, uterus, thymus, and adipose tissue responded similarly in R264A and WT female mice after estrogen treatment. In conclusion, our novel finding that mutation of R264 in ERα does not affect the regulation of the skeleton, together with the known role of R264 for ERα-mediated endothelial effects, supports the concept that R264 determines tissue specificity of ERα.NEW & NOTEWORTHY Mutation of arginine 264 in ERα has been shown to abrogate rapid membrane ERα-mediated endothelial effects. Our novel finding that mutation of R264 is dispensable for ERα-mediated skeletal effects supports the concept that R264 determines tissue specificity of ERα. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. WNT16 overexpression partly protects against glucocorticoid-induced bone loss
- Author
-
Ohlsson, Claes, primary, Nilsson, Karin H., additional, Henning, Petra, additional, Wu, Jianyao, additional, Gustafsson, Karin L., additional, Poutanen, Matti, additional, Lerner, Ulf H., additional, and Movérare-Skrtic, Sofia, additional
- Published
- 2018
- Full Text
- View/download PDF
8. Development of a synbiotic that protects against ovariectomy-induced trabecular bone loss.
- Author
-
Lawenius L, Gustafsson KL, Wu J, Nilsson KH, Movérare-Skrtic S, Schott EM, Soto-Girón MJ, Toledo GV, Sjögren K, and Ohlsson C
- Subjects
- Amino Acids, Branched-Chain, Animals, Bacteria, Fatty Acids, Volatile, Female, Humans, Mice, Ovariectomy, Vitamin K 2, Cancellous Bone, Synbiotics
- Abstract
The gut microbiome has the capacity to regulate bone mass. The aim of this study was to develop a nutritional synbiotic dietary assemblage at an optimal dose to maintain bone mass in ovariectomized (Ovx) mice. We performed genomic analyses and in vitro experiments in a large collection of bacterial and fungal strains (>4,000) derived from fresh fruit and vegetables to identify candidates with the synergistic capacity to produce bone-protective short-chain fatty acids (SCFA) and vitamin K2. The candidate SBD111-A, composed of Lactiplantibacillus plantarum , Levilactobacillus brevis , Leuconostoc mesenteroides , Pseudomonas fluorescens , and Pichia kudriavzevii together with prebiotic dietary fibers, produced high levels of SCFA in vitro and protected against Ovx-induced trabecular bone loss in a dose-dependent manner in mice. Metagenomic sequencing revealed that SBD111-A changed the taxonomic composition and enriched specific pathways for synthesis of bone-protective SCFA, vitamin K2, and branched-chain amino acids in the gut microbiome. NEW & NOTEWORTHY We performed genomic analyses and in vitro experiments in a collection of bacterial and fungal strains. We identified a combination (SBD111-A) that produced high levels of SCFA in vitro and protected against ovariectomy-induced bone loss in a dose-dependent manner in mice. Metagenomic sequencing revealed that SBD111-A changed the taxonomic composition and function of the gut microbiome and enriched pathways for synthesis of bone-protective SCFA, vitamin K2, and branched-chain amino acids.
- Published
- 2022
- Full Text
- View/download PDF
9. Estradiol and RSPO3 regulate vertebral trabecular bone mass independent of each other.
- Author
-
Nilsson KH, Wu J, Gustafsson KL, El Shahawy M, Koskela A, Tuukkanen J, Tuckermann J, Henning P, Lerner UH, Ohlsson C, and Movérare-Skrtic S
- Subjects
- Animals, Bone Density, Cancellous Bone metabolism, Estradiol pharmacology, Estrogens pharmacology, Female, Humans, Mice, Ovariectomy, Thrombospondins genetics, Thrombospondins pharmacology, Fractures, Bone, Osteoporosis genetics, Osteoporosis metabolism
- Abstract
Osteoporosis is an age-dependent serious skeletal disease that leads to great suffering for the patient and high social costs, especially as the global population reaches higher age. Decreasing estrogen levels after menopause result in a substantial bone loss and increased fracture risk, whereas estrogen treatment improves bone mass in women. RSPO3, a secreted protein that modulates WNT signaling, increases trabecular bone mass and strength in the vertebrae of mice, and is associated with trabecular density and risk of distal forearm fractures in humans. The aim of the present study was to determine if RSPO3 is involved in the bone-sparing effect of estrogens. We first observed that estradiol (E2) treatment increases RSPO3 expression in bone of ovariectomized (OVX) mice, supporting a possible role of RSPO3 in the bone-sparing effect of estrogens. As RSPO3 is mainly expressed by osteoblasts in the bone, we used a mouse model devoid of osteoblast-derived RSPO3 ( Runx2-creRspo3
flox/flox mice) to determine if RSPO3 is required for the bone-sparing effect of E2 in OVX mice. We confirmed that osteoblast-specific RSPO3 inactivation results in a substantial reduction in trabecular bone mass and strength in the vertebrae. However, E2 increased vertebral trabecular bone mass and strength similarly in mice devoid of osteoblast-derived RSPO3 and control mice. Unexpectedly, osteoblast-derived RSPO3 was needed for the full estrogenic response on cortical bone thickness. In conclusion, although osteoblast-derived RSPO3 is a crucial regulator of vertebral trabecular bone, it is required for a full estrogenic effect on cortical, but not trabecular, bone in OVX mice. Thus, estradiol and RSPO3 regulate vertebral trabecular bone mass independent of each other. NEW & NOTEWORTHY Osteoblast-derived RSPO3 is known to be a crucial regulator of vertebral trabecular bone. Our new findings show that RSPO3 and estrogen regulate trabecular bone independent of each other, but that RSPO3 is necessary for a complete estrogenic effect on cortical bone.- Published
- 2022
- Full Text
- View/download PDF
10. The effects of estradiol are modulated in a tissue-specific manner in mice with inducible inactivation of ERα after sexual maturation.
- Author
-
Ohlsson C, Farman HH, Gustafsson KL, Wu J, Henning P, Windahl SH, Sjögren K, Gustafsson JÅ, Movérare-Skrtic S, and Lagerquist MK
- Subjects
- Animals, Bone and Bones metabolism, Estrogen Receptor alpha genetics, Female, Mice, Mice, Transgenic, Organ Size drug effects, Ovariectomy, Thymus Gland drug effects, Thymus Gland metabolism, Uterus metabolism, Bone Density drug effects, Bone and Bones drug effects, Estradiol pharmacology, Estrogen Receptor alpha metabolism, Uterus drug effects
- Abstract
Mouse models with lifelong inactivation of estrogen receptor-α (ERα) show that ERα is the main mediator of estrogenic effects in bone, thymus, uterus, and fat. However, ERα inactivation early in life may cause developmental effects that confound the adult phenotypes. To address the specific role of adult ERα expression for estrogenic effects in bone and other nonskeletal tissues, we established a tamoxifen-inducible ERα-inactivated model by crossing CAGG-Cre-ER and ERα
flox/flox mice. Tamoxifen-induced ERα inactivation after sexual maturation substantially reduced ERα mRNA levels in cortical bone, trabecular bone, thymus, uterus, gonadal fat, and hypothalamus, in CAGG-Cre-ERαflox/flox (inducible ERαKO ) compared with ERαflox/flox (control) mice. 17β-estradiol (E2) treatment increased trabecular bone volume fraction (BV/TV), cortical bone area, and uterine weight, while it reduced thymus weight and fat mass in ovariectomized control mice. The estrogenic responses were substantially reduced in inducible ERαKO mice compared with control mice on BV/TV (-67%), uterine weight (-94%), thymus weight (-70%), and gonadal fat mass (-94%). In contrast, the estrogenic response on cortical bone area was unaffected in inducible ERαKO compared with control mice. In conclusion, using an inducible ERαKO model, not confounded by lack of ERα during development, we demonstrate that ERα expression in sexually mature female mice is required for normal E2 responses in most, but not all, tissues. The finding that cortical, but not trabecular bone, responds normally to E2 treatment in inducible ERαKO mice strengthens the idea of cortical and trabecular bone being regulated by estrogen via different mechanisms.- Published
- 2020
- Full Text
- View/download PDF
11. Pasteurized Akkermansia muciniphila protects from fat mass gain but not from bone loss.
- Author
-
Lawenius L, Scheffler JM, Gustafsson KL, Henning P, Nilsson KH, Colldén H, Islander U, Plovier H, Cani PD, de Vos WM, Ohlsson C, and Sjögren K
- Subjects
- Adipose Tissue metabolism, Akkermansia, Animals, Calcium Channels metabolism, Colon drug effects, Colon microbiology, Female, Femur drug effects, Lymph Nodes cytology, Mice, Mice, Inbred C57BL, Ovariectomy, Parathyroid Hormone metabolism, Pasteurization, Serum Amyloid A Protein metabolism, Spine drug effects, T-Lymphocytes, Regulatory, TRPV Cation Channels metabolism, Adipose Tissue growth & development, Gastrointestinal Microbiome physiology, Osteoporosis metabolism, Probiotics pharmacology, Verrucomicrobia metabolism
- Abstract
Probiotic bacteria can protect from ovariectomy (ovx)-induced bone loss in mice. Akkermansia muciniphila is considered to have probiotic potential due to its beneficial effect on obesity and insulin resistance. The purpose of the present study was to determine if treatment with pasteurized Akkermansia muciniphila (p Akk) could prevent ovx-induced bone loss. Mice were treated with vehicle or p Akk for 4 wk, starting 3 days before ovx or sham surgery. Treatment with p Akk reduced fat mass accumulation confirming earlier findings. However, treatment with p Akk decreased trabecular and cortical bone mass in femur and vertebra of gonadal intact mice and did not protect from ovx-induced bone loss. Treatment with p Akk increased serum parathyroid hormone (PTH) levels and increased expression of the calcium transporter Trpv5 in kidney suggesting increased reabsorption of calcium in the kidneys. Serum amyloid A 3 (SAA3) can suppress bone formation and mediate the effects of PTH on bone resorption and bone loss in mice and treatment with p Akk increased serum levels of SAA3 and gene expression of Saa3 in colon. Moreover, regulatory T cells can be protective of bone and p Akk -treated mice had decreased number of regulatory T cells in mesenteric lymph nodes and bone marrow. In conclusion, treatment with p Akk protected from ovx-induced fat mass gain but not from bone loss and reduced bone mass in gonadal intact mice. Our findings with p Akk differ from some probiotics that have been shown to protect bone mass, demonstrating that not all prebiotic and probiotic factors have the same effect on bone.
- Published
- 2020
- Full Text
- View/download PDF
12. WNT16 overexpression partly protects against glucocorticoid-induced bone loss.
- Author
-
Ohlsson C, Nilsson KH, Henning P, Wu J, Gustafsson KL, Poutanen M, Lerner UH, and Movérare-Skrtic S
- Subjects
- Animals, Bone Density drug effects, Bone Diseases, Metabolic prevention & control, Female, Mice, Mice, Inbred C57BL, Mice, Transgenic, Osteoblasts drug effects, Osteoblasts metabolism, Osteoporosis chemically induced, Osteoporosis genetics, Osteoporosis prevention & control, Prednisolone adverse effects, Up-Regulation genetics, Wnt Proteins metabolism, Bone Diseases, Metabolic chemically induced, Bone Diseases, Metabolic genetics, Cytoprotection genetics, Glucocorticoids adverse effects, Wnt Proteins genetics
- Abstract
Therapeutic use of glucocorticoids (GCs) is a major cause of secondary osteoporosis, but the molecular mechanisms responsible for the deleterious effects of GCs in bone are only partially understood. WNT16 is a crucial physiological regulator of bone mass and fracture susceptibility, and we hypothesize that disturbed WNT16 activity might be involved in the deleterious effects of GC in bone. Twelve-week-old female Obl-Wnt16 mice (WNT16 expression driven by the rat procollagen type I α1 promoter) and wild-type (WT) littermates were treated with prednisolone (7.6 mg·kg
-1 ·day-1 ) or vehicle for 4 wk. We first observed that GC treatment decreased the Wnt16 mRNA levels in bone of female mice (-56.4 ± 6.1% compared with vehicle, P < 0.001). We next evaluated if WNT16 overexpression protects against GC-induced bone loss. Dual-energy X-ray absorptiometry analyses revealed that GC treatment decreased total body bone mineral density in WT mice (-3.9 ± 1.2%, P = 0.028) but not in Obl-Wnt16 mice (+1.3 ± 1.4%, nonsignificant). Microcomputed tomography analyses showed that GC treatment decreased trabecular bone volume fraction (BV/TV) of the femur in WT mice ( P = 0.019) but not in Obl-Wnt16 mice. Serum levels of the bone formation marker procollagen type I N-terminal propeptide were substantially reduced by GC treatment in WT mice (-50.3 ± 7.0%, P = 0.008) but not in Obl-Wnt16 mice (-3.8 ± 21.2%, nonsignificant). However, the cortical bone thickness in femur was reduced by GC treatment in both WT mice and Obl-Wnt16 mice. In conclusion, GC treatment decreases Wnt16 mRNA levels in bone and WNT16 overexpression partly protects against GC-induced bone loss.- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.